As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

The company's worst days might be behind it.

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

These popular weight loss medications can come with unwanted side effects—especially if you continue to eat a high-fat diet. Here's what to know and how to avoid it.

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...